Literature DB >> 33317149

Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma.

Francesca Ida Montalto1,2, Francesca De Amicis1,2.   

Abstract

Cyclin D1, an important regulator of cell cycle, carries out a central role in the pathogenesis of cancer determining uncontrolled cellular proliferation. In normal cells, Cyclin D1 expression levels are strictly regulated, conversely, in cancer, its activity is intensified in various manners. Different studies demonstrate that CCDN1 gene is amplified in several tumor types considering it as a negative prognostic marker of this pathology. Cyclin D1 is known for its role in the nucleus, but recent clinical studies associate the amount located in the cytoplasmic membrane with tumor invasion and metastasis. Cyclin D1 has also other functions: it governs the expression of specific miRNAs and it plays a crucial role in the tumor-stroma interactions potentiating most of the cancer hallmarks. In the present review, we will summarize the current scientific evidences that highlight the involvement of Cyclin D1 in the pathogenesis of different types of cancer, best of all in breast cancer. We will also focus on recent insights regarding the Cyclin D1 as molecular bridge between cell cycle control, adhesion, invasion, and tumor/stroma/immune-system interplay in cancer.

Entities:  

Keywords:  breast cancer; cell cycle; cyclin D1; oncogenic properties; tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 33317149      PMCID: PMC7763888          DOI: 10.3390/cells9122648

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  97 in total

1.  D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability.

Authors:  K E Knudsen; W K Cavenee; K C Arden
Journal:  Cancer Res       Date:  1999-05-15       Impact factor: 12.701

Review 2.  The microenvironment of the tumour-host interface.

Authors:  L A Liotta; E C Kohn
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

3.  Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.

Authors:  A S Lundberg; R A Weinberg
Journal:  Mol Cell Biol       Date:  1998-02       Impact factor: 4.272

4.  Cytoplasmic cyclin D1 regulates glioblastoma dissemination.

Authors:  Tània Cemeli; Marta Guasch-Vallés; Mireia Nàger; Isidre Felip; Serafí Cambray; Maria Santacana; Sònia Gatius; Neus Pedraza; Xavier Dolcet; Francisco Ferrezuelo; Alberto J Schuhmacher; Judit Herreros; Eloi Garí
Journal:  J Pathol       Date:  2019-05-16       Impact factor: 7.996

5.  Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.

Authors:  Chenguang Wang; Saijun Fan; Zhiping Li; Maofu Fu; Mahadev Rao; Yongxian Ma; Michael P Lisanti; Chris Albanese; Benita S Katzenellenbogen; Peter J Kushner; Barbara Weber; Eliot M Rosen; Richard G Pestell
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

6.  Genomic organization, chromosomal localization, and independent expression of human cyclin D genes.

Authors:  T Inaba; H Matsushime; M Valentine; M F Roussel; C J Sherr; A T Look
Journal:  Genomics       Date:  1992-07       Impact factor: 5.736

7.  Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth.

Authors:  Timothy G Pestell; Xuanmao Jiao; Mukesh Kumar; Amy R Peck; Marco Prisco; Shengqiong Deng; Zhiping Li; Adam Ertel; Mathew C Casimiro; Xiaoming Ju; Agnese Di Rocco; Gabriele Di Sante; Sanjay Katiyar; Alison Shupp; Michael P Lisanti; Pooja Jain; Kongming Wu; Hallgeir Rui; Douglas C Hooper; Zuoren Yu; Aaron R Goldman; David W Speicher; Lisa Laury-Kleintop; Richard G Pestell
Journal:  Oncotarget       Date:  2017-08-04

8.  Amplification of the EGFR and CCND1 Are Coordinated and Play Important Roles in the Progression of Oral Squamous Cell Carcinomas.

Authors:  Huei-Tzu Chien; Sou-De Cheng; Chun-Ta Liao; Hung-Ming Wang; Shiang-Fu Huang
Journal:  Cancers (Basel)       Date:  2019-05-31       Impact factor: 6.639

9.  CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors.

Authors:  Yu Chen; Yingying Huang; Xuan Gao; Yi Li; Jing Lin; Lizhu Chen; Lianpeng Chang; Gang Chen; Yanfang Guan; Leong Kin Pan; Xuefeng Xia; Zengqing Guo; Jianji Pan; Yaping Xu; Xin Yi; Chuanben Chen
Journal:  Front Immunol       Date:  2020-08-10       Impact factor: 7.561

10.  Cytoplasmic cyclin D1 regulates cell invasion and metastasis through the phosphorylation of paxillin.

Authors:  Noel P Fusté; Rita Fernández-Hernández; Tània Cemeli; Cristina Mirantes; Neus Pedraza; Marta Rafel; Jordi Torres-Rosell; Neus Colomina; Francisco Ferrezuelo; Xavier Dolcet; Eloi Garí
Journal:  Nat Commun       Date:  2016-05-16       Impact factor: 14.919

View more
  32 in total

1.  A Notch inhibitor plus Resveratrol induced blockade of autophagy drives glioblastoma cell death by promoting a switch to apoptosis.

Authors:  Francesca Giordano; Francesca Ida Montalto; Maria Luisa Panno; Sebastiano Andò; Francesca De Amicis
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 2.  Advances in the research of plant-derived natural products against retinoblastoma.

Authors:  Jing-Chen Liu; Chun-Li Zhang; Kai-Ye Dong; Ming-Jun Li; Shu-Guang Sun; Cai-Rui Li
Journal:  Int J Ophthalmol       Date:  2022-08-18       Impact factor: 1.645

3.  Resveratrol Downregulates miR-155-5p to Block the Malignant Behavior of Gastric Cancer Cells.

Authors:  Nana Su; Lanlan Li; Erle Zhou; Hong Li; Shuhua Wu; Zhang Cao
Journal:  Biomed Res Int       Date:  2022-06-25       Impact factor: 3.246

4.  Cold Atmospheric Plasma Boosts Virus Multiplication via EGFR(Tyr1068) Phosphorylation-Mediated Control on Cell Mitophagy.

Authors:  Peiyu Han; Li Shen; Nan Nan; Renwu Zhou; Tianci Li; Xiaofeng Dai
Journal:  Int J Biol Sci       Date:  2022-05-09       Impact factor: 10.750

5.  CircRNA protein tyrosine phosphatase receptor type a suppresses proliferation and induces apoptosis of lung adenocarcinoma cells via regulation of microRNA-582-3p.

Authors:  Jixin Jiang; Hui Ge; Jie Yang; Yunfei Qiao; Xingxiang Xu; Yanming Geng
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

6.  HAPLN1 Affects Cell Viability and Promotes the Pro-Inflammatory Phenotype of Fibroblast-Like Synoviocytes.

Authors:  Yong Chen; Baojiang Wang; Yanjuan Chen; Qunyan Wu; Wing-Fu Lai; Laiyou Wei; Kutty Selva Nandakumar; Dongzhou Liu
Journal:  Front Immunol       Date:  2022-06-02       Impact factor: 8.786

7.  Comprehensive Computational Analysis of Honokiol Targets for Cell Cycle Inhibition and Immunotherapy in Metastatic Breast Cancer Stem Cells.

Authors:  Skolastika Skolastika; Naufa Hanif; Muthi Ikawati; Adam Hermawan
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-08       Impact factor: 2.650

8.  MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of β-Catenin and c-Myc.

Authors:  Eleni Anastasiadou; Elena Messina; Tiziana Sanavia; Lucia Mundo; Federica Farinella; Stefano Lazzi; Francesca Megiorni; Simona Ceccarelli; Paola Pontecorvi; Francesco Marampon; Cira Rosaria Tiziana Di Gioia; Giorgia Perniola; Pierluigi Benedetti Panici; Lorenzo Leoncini; Pankaj Trivedi; Andrea Lenzi; Cinzia Marchese
Journal:  Cells       Date:  2021-03-01       Impact factor: 6.600

9.  Induction of epithelial-mesenchymal transition (EMT) by hypoxia-induced lncRNA RP11-367G18.1 through regulating the histone 4 lysine 16 acetylation (H4K16Ac) mark.

Authors:  Pei-Hua Peng; Joseph Chieh-Yu Lai; Jeng-Shou Chang; Kai-Wen Hsu; Kou-Juey Wu
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

Review 10.  CDK4/6 Inhibitors in Melanoma: A Comprehensive Review.

Authors:  Mattia Garutti; Giada Targato; Silvia Buriolla; Lorenza Palmero; Alessandro Marco Minisini; Fabio Puglisi
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.